Prasugrel holds up against clopidogrel in second Japanese study
This article was originally published in Scrip
Executive Summary
Following the first filing in Japan last month for prasugrel hydrochloride, Daiichi Sankyo has released results from another of the local Phase III trials it is using to support the planned approval of the oral antiplatelet agent.